Encompass More Asset Management Makes New $919,000 Investment in IDEXX Laboratories, Inc. $IDXX

Encompass More Asset Management purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,439 shares of the company’s stock, valued at approximately $919,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC raised its stake in IDEXX Laboratories by 2.3% in the second quarter. Geode Capital Management LLC now owns 2,464,290 shares of the company’s stock valued at $1,317,875,000 after purchasing an additional 54,402 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of IDEXX Laboratories by 156.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock worth $778,439,000 after buying an additional 884,808 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of IDEXX Laboratories by 37.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,076,429 shares of the company’s stock valued at $452,046,000 after buying an additional 290,551 shares in the last quarter. William Blair Investment Management LLC lifted its holdings in shares of IDEXX Laboratories by 7.5% during the 2nd quarter. William Blair Investment Management LLC now owns 685,088 shares of the company’s stock worth $367,440,000 after acquiring an additional 47,977 shares during the last quarter. Finally, Legal & General Group Plc grew its position in IDEXX Laboratories by 1.8% in the second quarter. Legal & General Group Plc now owns 648,626 shares of the company’s stock worth $347,884,000 after acquiring an additional 11,768 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the transaction, the executive vice president owned 21,149 shares in the company, valued at approximately $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.98% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on IDXX shares. JPMorgan Chase & Co. raised their price target on IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 29th. Barclays assumed coverage on IDEXX Laboratories in a research report on Monday, December 8th. They issued an “overweight” rating and a $850.00 target price for the company. Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Finally, Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a report on Monday, November 3rd. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $763.50.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $688.48 on Monday. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.18 and a quick ratio of 0.87. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The business’s 50 day simple moving average is $695.70 and its two-hundred day simple moving average is $632.85. The stock has a market capitalization of $54.98 billion, a P/E ratio of 54.60, a price-to-earnings-growth ratio of 4.11 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The firm had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the firm posted $2.80 earnings per share. The business’s quarterly revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.